Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being...
Saved in:
| Main Authors: | Antonela Njavro, Jure Murgić, Blanka Jakšić, Marin Prpić, Angela Prgomet Sečan, Dražen Huić, Dinko Franceschi, Ana Fröbe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/467298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making
by: Antonela Njavro, et al.
Published: (2024-01-01) -
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01) -
Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01) -
LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01) -
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)